Dynamic quotes: Off
|
Company Description (as filed with the SEC)
We are a leader in the development of innovative device-based solutions in permanent birth control. We manufacture and market our proprietary Essure® permanent birth control system, which is the most effective non-surgical permanent birth control available based on a comparison of five-year clinical trial data. The Essure procedure delivers a soft and flexible insert into a woman’s fallopian tubes, causing a benign tissue in-growth which blocks the fallopian tubes. Successfully placed Essure inserts and the subsequent tissue growth around and through the inserts prohibits the egg from traveling through the fallopian tube, preventing conception. The effectiveness rate of the Essure system as determined in our clinical study is 99.83% after five years of follow-up. We obtained approval to market the Essure system in the European Union in February 2001 and obtained the U.S. Food and Drug Administration (“FDA”), approval for the Essure system in November 2002. ... More ...
Analyst Info |
|
| Annual EPS Est: | $0.16 |
| Quarterly EPS Est: | 0.06 |
| PEG Ratio: | 5.95 |
|
Mean Recommendation: View Summary / View All |
2.67 |
Data is provided by Zacks Investment Research

